Medpace Holdings, Inc. Stock

Equities

MEDP

US58506Q1094

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-05-21 EDT 5-day change 1st Jan Change
396.6 USD -0.15% Intraday chart for Medpace Holdings, Inc. -0.47% +29.40%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2024 * 2.17B 2.96B Sales 2025 * 2.52B 3.44B Capitalization 12.28B 16.76B
Net income 2024 * 360M 491M Net income 2025 * 420M 573M EV / Sales 2024 * 5.33 x
Net cash position 2024 * 715M 976M Net cash position 2025 * 1.05B 1.43B EV / Sales 2025 * 4.46 x
P/E ratio 2024 *
35.4 x
P/E ratio 2025 *
30.3 x
Employees 5,800
Yield 2024 *
-
Yield 2025 *
-
Free-Float 81.97%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.15%
1 week-0.47%
Current month+2.14%
1 month+5.42%
3 months+2.67%
6 months+43.57%
Current year+29.40%
More quotes
1 week
386.33
Extreme 386.3272
407.97
1 month
355.79
Extreme 355.79
421.00
Current year
277.72
Extreme 277.72
421.00
1 year
197.39
Extreme 197.39
421.00
3 years
126.95
Extreme 126.945
421.00
5 years
53.10
Extreme 53.1
421.00
10 years
21.76
Extreme 21.76
421.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 67 92-06-30
Director of Finance/CFO 49 18-10-31
President 49 07-09-30
Members of the board TitleAgeSince
Director/Board Member 72 18-08-12
Chief Executive Officer 67 92-06-30
Director/Board Member 64 18-08-12
More insiders
Date Price Change Volume
24-05-21 396.6 -0.15% 161 429
24-05-20 397.2 +1.00% 99,546
24-05-17 393.3 +0.01% 118,741
24-05-16 393.3 -3.10% 154,914
24-05-15 405.9 +1.85% 227,640

Delayed Quote Nasdaq, May 21, 2024 at 04:00 pm

More quotes
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
397.2 USD
Average target price
423.2 USD
Spread / Average Target
+6.52%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW